Document is current
Any future updates will be listed below
-
Authors
Stange, Christoph
Dreyer, Tobias F.
Riedel, Maximilian
Elsen, Franziska
Seitz, Stefanie
Hamann, Dorine
Kiechle, Marion https://orcid.org/0000-0003-4237-2657
Bronger, Holger https://orcid.org/0000-0002-3706-6738
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BR4733/3-1, and BR/4733/4 1, BR4733/3-1, BR4733/3-1, BR4733/3-1, BR4733/3-1, BR4733/3-1, BR4733/3-1, BR4733/3-1)
Wilhelm Sander-Stiftung (2019.085.1)
- License Information
-
More Information
Article History
Received: 29 September 2024
Revised: 6 May 2025
Accepted: 23 May 2025
First Online: 27 June 2025
Competing interests
: MK reports remunerations by Springer Press, Biermann Press, Celgene, Astra Zeneca, Myriad Genetics, TEVA, Eli Lilly, GSK, consulting for Myriad Genetics, Bavarian KVB, DKMS Life, BLAEK, TEVA, Exeltis, equity ownership in Therawis Diagnostic GmbH, AIM GmbH, funding from Sphingotec, Deutsche Krebshilfe, DFG, Senator Roesner Foundation, Dr. Pommer-Jung Foundation, Waltraut Bergmann Foundation, Bavarian State Ministry of Economy, BMBF. HB reports grants from the German Research Foundation (DFG) during the conduct of the study, as well as personal fees from Roche, AstraZeneca, MSD, Pharma&, AbbVie, and GlaxoSmithKline outside the submitted work. The other authors declare no potential conflicts of interest.
: The use of human samples was approved by the Institutional Review Board of the Technical University of Munich (Munich, Germany; approval 392/17S). Animal experiments were approved by the Government of Upper Bavaria (Regierung von Oberbayern) and were in accordance with the institutional guidelines of the Technical University of Munich. The study was performed in accordance with the Declaration of Helsinki.
